Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Jan;36(1):75-83.
doi: 10.1002/art.1780360113.

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

P J Clements  1 , P A Lachenbruch, M Sterz, G Danovitch, R Hawkins, A Ippoliti, H E Paulus
Affiliations
Clinical Trial

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

P J Clements et al. Arthritis Rheum. 1993 Jan.

Abstract

Objective: To evaluate safety and efficacy of cyclosporin A (CSA) treatment in systemic sclerosis (SSc).

Methods: Ten patients with < or = 60 months of SSc were entered into a 48-week open study of CSA. Patients with hypertension or azotemia were excluded. Concurrent use of nonsteroidal antiinflammatory agents or diuretics was not permitted. The extent of cutaneous and visceral involvement at 48 weeks and at study entry were compared.

Results: Adverse reactions (especially nephrotoxicity) were frequent, usually transient, often dose-limiting, and usually associated with CSA doses > or = 3-4 mg/kg/day. Skin thickening decreased significantly (P < 0.001), while pulmonary and cardiac involvement remained unchanged.

Conclusion: CSA should undergo blinded controlled study in patients with SSc.

PubMed Disclaimer

Comment in

Publication types

LinkOut - more resources